• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CTTI takes on site investigator turnover in new recommendations

CTTI takes on site investigator turnover in new recommendations

October 6, 2017
CenterWatch Staff

The Clinical Trials Transformation Initiative (CTTI) unveiled new recommendations aimed at reducing high rates of turnover among U.S. clinical trial site investigators at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit on Oct. 7. CTTI’s practical solutions address the administrative, financial, and logistical burdens that are causing investigators to abandon clinical research.

“One thing we’ve seen from our work in this area is that there’s no shortage of physicians interested in participating as trial investigators,” said Duke cardiologist Dr. Matthew Roe, co-team leader for CTTI’s Investigator Community Project. “The problem is that leading a trial is complex and the learning curve is steep. If you’re new to the field or you don’t have mentors, training, and infrastructure to support you, the burdens can quickly become overwhelming and lead to an investigator only doing a single trial—something we call ‘one and done’. Then the imperfect cycle begins again with a new investigator.”

Drawing on combined experience and insight from investigators, sponsors, CROs, patients, regulators, and representatives from clinical research professional societies and trade associations, CTTI identified the key challenges facing investigative sites.

“For an investigator to effectively manage their site and study there are many elements that must be given serious consideration—and are often unknown at the onset of the first study—to ensure they do not become a ‘one and done,’” said Christine Pierre, president of SCRS. “These recommendations help guide that direction for the site and the rest of the industry. The true impact will only be realized when all stakeholders embraces these recommendations.”

Although the CTTI recommendations were tailored for action by different stakeholders—investigators, sponsors, contract research organizations, and health systems—strategies such as supporting continuous training, maintaining clear communications and operational procedures, and fostering a climate of mutual respect emerged as cross-cutting themes.

“These recommendations are a blueprint for creating a system that supports successful and sustainable clinical trials,” noted Sheryl Jacobs, vice president of Global Development Operations at Amgen. “The Investigator Community Project provides straightforward, actionable steps that the biopharmaceutical industry can take to ensure that clinical research remains an attractive arena for skilled and talented people looking to make a difference in patients’ lives.”

The new recommendations will be the focus of a panel discussion taking place at SCRS’ Global Site Solutions Summit on Oct. 7 from 4:30-5:30 p.m. EDT. CTTI will also present the recommendations during a public webinar on Oct. 19 at noon EDT.

Global Funding for this project was made possible, in part, by the FDA through grant 5R18FD005292-04, views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices or organization imply endorsement by the United States Government.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing